Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose NUI Galway as their University of choice. Find out what life at NUI Galway is all about here.
About NUI Galway
About NUI Galway
Since 1845, NUI Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
NUI Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
- Business & Industry
- Alumni, Friends & Supporters
At NUI Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
February 2017 CÚRAM Investigators Awarded €150,000 to Tackle Major Global Health Problems
CÚRAM at NUI Galway win European Research Council grant to support the development of a new medical device to treat high blood pressure that can lead to heart disease and stroke
Tuesday, 21 February, 2017: CÚRAM Investigator Dr Martin O’Halloran has been awarded a second European Research Council (ERC) grant. ERC grants are Europe's most competitive and prestigious research funding, and in this case the €150,000 award will support the development of a new medical device for the treatment of hypertension (high blood pressure) that can lead to heart disease and stroke.
The project is a collaboration between Investigators Dr Martin O’Halloran and Dr Conall Dennedy at CÚRAM, the Centre for Research in Medical Devices based at NUI Galway. The Investigators aim to bring the novel medical device towards first-in-man trials within the lifetime of the project. Since heart disease and stroke are such major global health problems affecting a large population of patients, the team expect the project to have a very significant societal and economic impact.
The widespread presence of hypertension in European countries is currently 28-44%. This amounts to between 200 and 327 million Europeans. Excess production of the hormone aldosterone by the adrenal glands (primary aldosteronism) is the most common endocrine cause and accounts for 8-20% of all hypertension. Current treatment regimens are dissatisfactory and costly, involving either surgery or lifelong drug therapy. Therefore, a cost-effective, minimally invasive and definitive management approach for this underlying cause would present a potential cure for an often undiagnosed and unmanaged disease. This is what is being proposed with the new ERC ‘REALTA’ project.
“The REALTA project plan is very similar to that of a start-up medtech company, where as well as technology development, the team will also examine the competitive landscape, the clinical and regulatory pathway, and reimbursement opportunities”, says Dr O’Halloran. “The overarching goal is to gather sufficient technical, clinical, regulatory and commercial evidence over the course of the next 18 months to be able to spin-out a company that is attractive to external investors. Such investment will be required to take the technology through to Food and Drug Administration (FDA) approval and clinical trials.”
Dr O’Halloran secured his first ERC Starting Grant in 2015 to examine the electrical properties of human tissue, as a platform for novel medical device development in Europe. Supported by a Science Foundation Ireland ERC Support Grant, he established the Translational Medical Device Lab in Galway, the first medical device lab in Ireland to be embedded in a regional hospital, University Hospital Galway, and co-located within the Health Research Board’s Clinical Research Facility. Working closely with Dr Conall Dennedy, Consultant Endocrinologist at NUI Galway, he began to examine the potential of new technologies to treat primary aldosteronism, the most common endocrine cause of hypertension.
Professor Abhay Pandit, Scientific Director of CÚRAM said: “The objectives of CÚRAM are to carry out research on the development of innovative ‘smart’ implantable medical devices, which will benefit patients with chronic ailments such as cardiovascular diseases. I would like to congratulate Dr O’Halloran and Dr Dennedy on their continued research success, which is supported by the excellent multidisciplinary team of clinicians, translational scientists and engineers here at CÚRAM and NUI Galway, which reflects the interests and expertise of investigators in CÚRAM.”
For more information on the Translational Medical Device Lab in NUI Galway visit: http://www.tmdlab.ie